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Abstract
Computed tomography (CT), the standard method to assess tumor response to
cetuximab in incurable squamous cell carcinoma of the head and neck
(SCCHN), performs poorly as judged by the disparity between high disease
control rate (46%) and short time to progression (TTP) (70 days). F-18 fluorodeoxyglucose positron emission tomography (FDG-PET)/CT is an alternative
method to assess tumor response. The primary objective of this prospective trial
was to evaluate the metabolic response of target lesions, assessed as the change
in maximum standardized uptake value (SUVmax) on FDG-PET/CT before and
after 8 weeks (cycle 1) of cetuximab. Secondary objectives were to compare
tumor response by CT (RECIST 1.0) and FDG-PET/CT (EORTC criteria)
following cycle 1, and determine TTP with continued cetuximab administration
in patients with disease control by CT after cycle 1 but stratified for disease
control or progression by FDG-PET/CT. Among 27 patients, the mean percent
change of SUVmax of target lesions after cycle 1 was 21% (range: +72% to
81%); by FDG-PET/CT, partial response (PR)/stable disease (SD) occurred in
15 patients (56%) and progression in 12 (44%), whereas by CT, PR/SD
occurred in 20 (74%) and progression in 7 (26%). FDG-PET/CT and CT
assessments were discordant in 14 patients (P = 0.0029) and had low agreement
(j = 0.30; 95% confidence interval [CI]: 0.12, 0.48). With disease control by
CT after cycle 1, median TTP was 166 days (CI: 86, 217) if the FDG-PET/CT
showed disease control and 105 days (CI: 66, 159) if the FDG-PET/CT showed
progression (P < 0.0001). Median TTP of the seven patients whose post cycle 1
CT showed progression compared to the 12 whose FDG-PET/CT showed
progression were similar (53 [CI: 49, 56] vs. 61 [CI: 50, 105] days, respectively).
FDG-PET/CT may be better than CT in assessing benefit of cetuximab in
incurable SCCHN.

Poster presentation was made at the ASCO
meeting of 2011.

Introduction
Cetuximab, a monoclonal antibody directed against the
epidermal growth factor receptor (EGFR), is the only targeted therapy approved for treatment of squamous cell

carcinoma of the head and neck (SCCHN). Indications
include use as a single agent in platinum-resistant disease
[1], in combination with chemotherapy for incurable disease [2], or concurrently with radiation therapy for locally
advanced disease [3]. Benefits of cetuximab include

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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improvement in tumor response, disease control and
overall survival (OS) [2, 3].
In incurable SCCHN, single-agent cetuximab resulted
in a tumor response rate of 13%, disease control rate of
46%, and median time to progression (TTP) and OS of
70 and 178 days, respectively [1]. A small fraction of
patients have progression-free survival for more than
6 months. Early identification of benefit from cetuximab
is important, since efficacy overall is limited.
Computed tomography (CT) is the standard method
for assessing tumor response to cetuximab in incurable
SCCHN. However, it is unclear if CT is the optimal
method, and it has not been prospectively compared to
alternative imaging modalities. Currently, biomarkers
that predict response of SCCHN to cetuximab do not
exist. Evidence supports investigation of positron emission tomography (PET) with F-18 fluorodeoxyglucose
(FDG)-PET/CT to evaluate tumor response to EGFR
inhibitors. Changes in FDG uptake correlated with
molecular response to the EGFR inhibitor erlotinib in
SCCHN cell lines and xenograft models and in a pilot
study of neoadjuvant erlotinib [4]. In a neoadjuvant trial
of cetuximab given to patients with SCCHN, changes in
FDG uptake correlated to declines in Ki-67 expression
and tumor cellularity [5]. In selected malignancies,
tumor response, TTP and OS with targeted therapy were
better predicted by sequential FDG-PET/CT than by CT
[6]. Several reviews highlighted the limitations of
anatomic imaging (by CT) using response evaluation
criteria in solid tumors (RECIST 1.0) [7], particularly
with respect to targeted therapy, and noted the benefits
of metabolic tumor response assessment with FDG-PET
[8, 9].
In this prospective trial, we sought to compare tumor
response assessment by CT and FDG-PET/CT following
8 weeks (cycle 1) of single-agent cetuximab administered
to patients with incurable SCCHN. In addition, we determined TTP with continued cetuximab administration in
patients with disease control by CT after cycle 1 but stratified for disease control or progression by FDG-PET/CT.

Materials and Methods
Patient selection
Eligible patients were 18 years of age and older with
incurable (metastatic or unresectable locoregional recurrence in a previously irradiated field) SCCHN. At least
one PET-measurable lesion was required, which we
defined as a lesion ≥1.5 cm by CT that was FDG avid
(maximum standardized uptake value [SUVmax] ≥ 3) by
FDG-PET/CT. Eastern Cooperative Oncology Group
(ECOG) performance status of 0–3 was acceptable. Prior
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therapy with an EGFR-specific monoclonal antibody was
allowed only if it was given as part of definitive treatment
for nonmetastatic disease occurring more than 3 months
beforehand. Exclusion criteria included cancer therapy
received within 14 days and prior grade 4 hypersensitivity
infusion reaction (HSR) to cetuximab. All study participants signed informed consent for this institutional
review board-approved, prospective trial (Clinicaltrials.gov NCT#00671437).

Treatment plan and standard assessments
Baseline assessments performed within 28 days of treatment included history taking and physical examination,
contrast-enhanced CT of neck and chest and FDG-PET/
CT. Cetuximab was given in 8 week cycles as a 400 mg/
m2 loading dose IV followed by weekly doses of 250 mg/
m2. One week (3 days) after cycle 1, patients underwent
assessment of tumor response with CT and FDG-PET/CT.
Tumor response was assessed by CT using RECIST 1.0
[7] and by FDG-PET/CT using the European Organization for Research and Treatment of Cancer (EORTC) criteria [10]. In brief, definitions of metabolic response by
FDG-PET/CT included: complete metabolic response
(CMR)—complete resolution of all metabolically active
target and nontarget lesions, and no new lesions; partial
metabolic response (PMR)—20% or greater decrease in
SUV of target lesions with or without decrease in number/size of nontarget lesions, and no new lesions; progressive metabolic disease (PMD)—one or more new lesions,
20% or greater increase in SUV of target lesions and/or
unequivocal increase in FDG activity of nontarget lesions;
and stable metabolic disease (SMD)—not qualifying as
CMR, PMR, or PMD.
Evaluation of response by CT with RECIST 1.0 was
performed by an independent radiologic reviewer
(M. J. S.). Target lesions were chosen based on the size
(≥1.0 cm) with inclusion of locoregional disease and distant metastases. Necrotic lesions were avoided. Patients
with disease control (complete response [CR], partial
response [PR] or stable disease [SD]) by RECIST 1.0 at
end of cycle 1 continued on treatment with cetuximab
until there was evidence of progressive disease by RECIST. CT scans were performed at the end of each cycle
of cetuximab; however, FDG-PET/CT was performed only
following cycle 1. Since little was known about the correlation of metabolic tumor response by FDG-PET/CT to
anatomic tumor response by CT with respect to TTP in
patients with SCCHN receiving cetuximab, the results of
the FDG-PET/CT were not used to define disease progression. Decisions about whether or not to continue cetuximab after cycle 1 were based on the tumor response
assessment by CT.

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Noniodine contrast-enhanced FDG-PET/CT was performed with one of several PET/CT scanners (Siemens Biograph 40HD (Siemens Medical Solutions USA, Inc.,
Malvern, PA), Siemens mCT (Siemens Medical Solutions
USA, Inc.), and GE Discovery STE, GE Healthcare,
Waukesha, WI) before and following 8 weeks of cetuximab
in accordance with the Division of Nuclear Medicine’s
standard procedures based on the National Cancer Institute
recommendations [11]. Both scans were performed on the
same model of scanner. The standard whole-body examination included images from the skull vertex to the upper
thighs, acquired in two acquisitions. The first acquisition
consisted of two bed positions from the skull vertex to the
lung apices and the second acquisition encompassed the
neck to the upper thighs. FDG, 10–15 mCi (dose adjusted
up to 25 mCi for obese subjects), was administered IV and
imaging was begun 60  10 min later. CT images used for
attenuation correction and image fusion were acquired at
120 kVp with 95–111 mAs. Emission scan duration ranged
from 2 to 5 min per bed position, depending on body
weight. Images were reconstructed at 5-mm slice thickness.
FDG-PET/CT images were evaluated qualitatively as well
as quantitatively by one of two experienced nuclear radiologists (F. D., B. A. S.). For quantitative analysis, SUVmax
within each of the tumor sites was determined within a volume of interest around the tumor using a Siemens eSoft
workstation (Siemens Medical Solutions USA, Inc.). Up to
a maximum of three target lesions (≥1.5 cm on the baseline
CT) were identified as target lesions on the baseline FDGPET. When multiple lesions were present, those having the
greatest FDG uptake on the baseline FDG-PET were selected
as target lesions. Lesions containing areas of necrosis were
avoided. Other metabolically active lesions and lesions that
were <1.5 cm on CT were considered nontarget lesions.
When more than one target lesion was identified, the average percentage change in SUVmax was used to determine
metabolic response. Target and nontarget lesions as defined
above for the FDG-PET component of the study may or
may not be the same target and nontarget lesions defined by
RECIST 1.0. However, one or more of the target lesions
identified on FDG-PET/CT were also identified as target
lesions on the CT scan in 25 of the 27 evaluable patients.

Statistical methods
Study objectives
The primary objective of the study was to compare the
SUVmax of up to three target lesions as assessed by FDGPET/CT performed before and after 8 weeks of cetuximab
given to patients with incurable SCCHN. Secondary
objectives included determining the overall tumor metabolic response (by FDG-PET/CT) and anatomic response

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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(by CT) rates after 8 weeks of cetuximab. The results of
tumor response as assessed by FDG-PET/CT and CT were
compared and were correlated to TTP.
Data analysis
This was a single stage, nonrandomized, prospective observational study to determine the changes in SUVmax on
FDG-PET/CT associated with 8 weeks of cetuximab therapy in patients with incurable SCCHN. For the primary
endpoint, we determined the SUVmax for one to three target tumor sites (with the highest SUVs) in each patient at
baseline and after cycle 1 of cetuximab. A clustered linear
repeated measures model was used to compare one to three
observations of SUV at two time points. SUV distribution
was analyzed on a log scale to approximate a Gaussian
distribution. Model fit was assessed using standardized and
scaled residuals. Mean SUVs pre and post 8 weeks of
cetuximab were estimated after adjusting for prior exposure to cetuximab, use of cetuximab as first-line therapy
and tumor site (oropharynx vs. other). A generalization of
McNemar’s test was used to test for concordance of
response (partial, stable or progression) by CT and by
FDG-PET/CT. Kaplan–Meier and Cox proportional hazard
models were used to describe the effects of metabolic and
anatomic response (disease control or progression) on
TTP. The proportional hazards assumption was examined
using plots, and deviance and martingale residuals were
examined to verify model fit.
Sample size and study power
Based on the institutional historical data, 40 new cases of
incurable SCCHN were expected to present within the
planned 2-year accrual period. Seventy percent, or 28
patients, were expected to (1) meet eligibility criteria, (2)
consent to participate on the study, and (3) have measurable FDG uptake at tumor sites. Of those 28 patients, ~3
were expected to discontinue therapy before the end of
cycle 1 of cetuximab therapy because of adverse events,
early disease progression, or other factors. The sample
available for analysis was expected to be 25 patients. When
the study was designed, little was known of the expected
metabolic response distribution by SCCHN tumors
obtained from patients at baseline and after cetuximab
therapy. However, as an estimate, a sample of 25 patients
provided at least 80% power at a 0.05 significance level if
FDG uptake (SUVmax) differed by 50% (e.g., means of 40
and 20 among nonresponders and responders, respectively)
with a standard deviation no greater than 16, or a coefficient of variation no larger than 0.4. Measures of agreement, time to event models, and proportional odds models
were considered exploratory, as the study generated
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estimates required to calculate study power and/or precision for these analyses in subsequent studies.
Thus, the study planned to enroll 42 patients, of whom
25 were expected to be evaluable. Evaluable patients were
defined as those patients who completed cycle 1 of cetuximab and underwent pre- and post treatment CT and
FDG-PET/CT. To accommodate one interim analysis and
a final analysis while maintaining an overall 0.05 significance level, P-values were adjusted for multiple looks at
the data using an O’Brien-Fleming test. The P-value for
the first interim analysis was 0.0052 and for the final
analysis 0.0480.

Results
Patient and tumor characteristics
Forty-two patients were enrolled onto the trial and 27
were evaluable for the objectives. All evaluable patients
had SCCHN, underwent CT and FDG-PET/CT before
and after cycle 1 of cetuximab, and were followed for the
TTP endpoint. Of the 15 nonevaluable patients, eight
developed rapidly progressive disease before week 8 of
cycle 1, three developed a HSR prompting discontinuation of cetuximab, three had cutaneous SCC of the head
and neck and were excluded, and one was deemed ineligible post hoc (target lesion <1.5 cm on FDG-PET/CT).
Most of the 27 evaluable patients were smokers with
SCCHN that recurred within 1 year of primary therapy
and had prior exposure to a platin agent (Table 1). Eight
patients (29.6%) had prior exposure to cetuximab, given
12 or more months before study enrollment. Approximately half of the patients had received prior chemotherapy for recurrent disease. The characteristics of the
evaluable patients and of all patients enrolled onto the
trial were similar.

Primary objective
The primary objective was to compare the SUVmax of up
to three target lesions as assessed by FDG-PET/CT before
and then after 8 weeks of cetuximab. A linear hierarchical
repeated measure model was used to estimate mean SUV
on a log scale before and after cycle 1 of cetuximab. The
model was adjusted for prior cetuximab exposure (yes/
no), first-line versus subsequent-line cetuximab treatment
(yes/no) and primary tumor site (oropharynx/other sites).
The reference P-value determining statistical significance
was .048 to adjust for one interim analysis. Mean log
SUVmax decreased with cycle 1 of cetuximab
(P = 0.0097). On the original scale, SUVmax decreased by
21% from a precetuximab mean of 9.3 (95% confidence
interval [CI]: 7.2, 12.1) to a post cycle 1 cetuximab mean
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Table 1. Patient, tumor, and treatment characteristics.
Characteristic

Evaluable number (n = 27)

Percent

Patient
Age (years) median (range)
63 (35–87)
–
Sex
Male
21
77.8
Female
6
22.2
Race
Caucasian
23
85.2
African-American
3
11.1
Asian
1
3.7
Performance status1
0
5
18.5
1
13
48.1
2
9
33.3
Smoking history
Yes
24
88.9
No
3
11.1
Interval from diagnosis to recurrence (months)
Median (range)
10 (0–43)
–
Tumor
Primary site
Oral cavity
10
37.0
Oropharynx
8
29.6
Larynx
4
14.8
Hypopharynx
5
18.5
HPV-related oropharynx only
3/8
–
Prior treatment for initial disease
Surgery
Yes
15
55.6
No
12
44.4
Radiation2
Yes
24
88.9
No
3
11.1
Chemotherapy3
Yes
9
33.3
No
18
66.7
Cetuximab
Yes
8
29.6
No
19
70.4
Interval from prior cetuximab treatment to recurrence (months)
Median (range)
18.5 (12–48)
–
Prior treatment for recurrent disease
Chemotherapy4
Platin
9
33.3
Taxane
9
33.3
Pemetrexed or 5-FU
3
11.1
3
11.1
Targeted therapy5
# Lines of chemotherapy
0
15
55.6
1
8
29.6
2–3
4
14.8
Prior platin exposure
Yes
17
63
No
10
37
1

ECOG–Eastern Cooperative Oncology Group.
Postoperative or definitive.
3
Induction and/or chemoradiation.
4
Patients may have received one or more agents.
5
Vandetanib (2); Bevacizumab (1); Gefitinib (1).
2

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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of 7.3 (CI: 5.6, 9.5) (Fig. 1A). The percent change in
SUVmax pre- and post cycle 1 of cetuximab grouped by
metabolic tumor response is shown in Figure 1B.

Table 2. Concordance between CT and FDG-PET/CT after cycle 1 of
cetuximab.
Response by CT at end of 1 cycle
Frequency

Overall anatomic and metabolic tumor
response, and concordance of FDG-PET/CT
and CT
Following cycle 1 of cetuximab, the overall anatomic
tumor responses assessed by CT were PR/SD in 20
patients (74%) and progression in seven patients (26%).
The overall metabolic tumor responses assessed by FDGPET/CT were PMR/SMD in 15 patients (56%) and PMD
in 12 patients (44%) (Table 2). A test for concordance
found that FDG-PET/CT and CT tumor response assessments were discordant in 14 of the 27 patients
(P = 0.0029) and had a low level of agreement (j = 0.30
with 95% CI: 0.12, 0.48). A comparison of the two
response variables illustrated the discordance in the form
of lower disease control by FDG-PET/CT relative to CT.
However, FDG-PET/CT was more likely to identify PR

FDG/PET SUVmax

A

13.0
12.5
12.0
11.5
11.0
10.5
10.0
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0

B

100

PMR

SMD

PMD

Total

1
9
0
10

0
5
0
5

0
5
7
12

1
19
7
27

FDG-PET/CT, F-18 fluorodeoxyglucose positron emission tomography/
computed tomography; PMR, partial metabolic response; SMD, stable
metabolic disease; PMD, progressive metabolic disease; PR, partial
response; SD, stable disease; PD, progressive disease.

(10 of 27) than CT (1 of 27); whereas CT was more likely
to identify patients as stable (19 of 27) than FDG-PET/
CT (5 of 27).
Mean percent changes of SUVmax of target lesions after
cycle 1 were 48% ( 24 to 81), 10% (0 to 17), and
+8% (+72 to 57) when overall tumor responses by FDGPET/CT were PMR, SMD, and PMD, respectively (Table 3).
Two patients with ≥20% decrease in SUVmax of target
lesions were classified as PMD because of interval increase in
the number, FDG uptake, and/or size of nontarget lesions.

Agreement in treatment decision between
CT and FDG-PET/CT

Pre cetuximab

Post cetuximab

75

Percent change in SUVmax

PR
SD
PD
Total

Overall PET response

50
25
0
–25
–50
–75
–100
PMR

SMD

PMD

Overall PET response

Figure 1. (A) Mean SUVmax pre and post cycle 1 of cetuximab
adjusted for prior cetuximab (yes/no), study treatment is first-line
cetuximab (yes/no) and tumor site (oropharynx/other). (B) Percent
change in SUVmax pre and post cycle 1 of cetuximab by FDG-PET/CT
response. SUVmax, maximum standardized uptake value; FDG-PET/CT,
F-18 fluorodeoxyglucose positron emission tomography/computed
tomography; PMR, partial metabolic response; SMD, stable metabolic
disease; PMD, progressive metabolic disease.

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

We assessed the agreement in treatment decision based
on the tumor response assessment by CT and FDG-PET/
CT following cycle 1 of cetuximab. For study purposes,
agreement in treatment decision was defined to occur
when tumor response assessment by CT and FDG-PET/
CT would have resulted in the same decision to either
continue cetuximab (if disease control) or to stop cetuximab (if progression). Conversely, disagreement in treatment decision was defined to occur when tumor response
assessment by CT and FDG-PET/CT would have resulted
in different treatment decisions. Using these clinically relevant definitions, we observed agreement in treatment
decision between the two imaging modalities after cycle 1
in 22 patients (81.4%) and disagreement in treatment
decision between the two imaging modalities in five
patients (18.6%) (Table 2). All five cases of disagreement
in treatment decision showed stable anatomic response by
CT and PMD by FDG-PET/CT. An example of disagreement in treatment decision between the two imaging
modalities is shown in Figure 2.

Tumor response and TTP
Cetuximab was continued after cycle 1 in patients with
disease control (PR/SD) by CT, even if the FDG-PET/CT
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Table 3. Metabolic tumor response assessment by FDG-PET/CT for the 27 evaluable patients.
Nontarget lesion(s)1

SUVmax
Overall response by
FDG-PET/CT (N = 27)

Patient
number

Number of
target lesion(s)

Baseline

Post 8 weeks
cetuximab

Partial (37%)

10
15
16
18
19
27
32
33
37
39
Mean of column
5
12
22
24
28
Mean of column
1
2
8
20
21
23
26
31
34
35
40
42
Mean of column

1
1
1
3
1
1
2
1
1
1
11 (1–3)
3
1
1
2
1
2 (1–3)
1
1
3
3
1
3
1
3
1
3
1
3
2 (1–3)

14.4
16.6
8.6
8.9
14.8
11.5
3.3
40.0
14.4
8.3
14.1 (3.3–40.0)
7.5
5.4
6.5
20.6
12.7
10.5 (5.4–20.6)
5.7
8.9
8
3.8
20.2
14.0
12.6
14.8
18.7
14.2
5.4
10.1
11.4 (3.8–20.2)

10.3
12.1
5.7
3.3
4.0
8.7
2.1
15.7
7.4
1.6
7.1 (1.6–15.7)
7.5
4.5
6.0
18.1
10.8
9.4 (4.5–18.1)
8.2
7.4
8
5.5
8.6
19.8
15.4
12.9
17.9
10.4
9.3
9.0
11.0 (5.5–19.8)

N = 10
Stable (19%)

N=5
Progression (44%)

N = 12

%
Change
29
27
34
63
73
24
36
61
49
81
48 ( 24 to 81)
0
17
8
12
15
10 (0 to 17)
+44
17
0
+45
57
+41
+22
13
4
27
+72
11
+8 (+72 to 57)

Number

SUV
uptake

Size

Stable
Stable
Stable
↓
↓
↓
↓
–
–
Stable

–
Stable
↓
↓
↓
↓
↓
–
–
Stable

–
Stable
Stable
↓
↓
↓
↓
–
–
Stable

Stable
Stable
Stable
–
Stable

Stable
Stable
Stable
–
Stable

Stable
Stable
Stable
–
Stable

–
Stable
↑
↑
↑
↑
Stable
Stable
↑
↑
↑
↑

–
↑
↑
↑
↑
↑
↑
Stable
↑
↑
↑
↑

–
↑
Stable
↑
↑
↑
↑
↑
↑
↑
Stable
↑

FDG-PET/CT, F-18 fluorodeoxyglucose positron emission tomography/computed tomography; SUVmax, maximum standardized uptake value.
–, Not applicable.

1

showed PMD. Cetuximab was discontinued after cycle 1
in patients with progression by CT. In the 20 evaluable
patients with disease control by CT after cycle 1, median
TTP was 166 days (CI: 86, 217) if the FDG-PET/CT
showed disease control (n = 15) and 105 days (CI: 66,
159) if the FDG-PET/CT showed progression (n = 5)
(P < 0.0001). All seven patients with progression by CT
after cycle 1 also had PMD by FDG-PET/CT. The median
TTP in these patients was 53 days (CI: 49, 56).
We compared the TTP in each tumor response group
between the two imaging modalities. Median TTP of the
20 patients whose post cycle 1 tumor response assessment
showed disease control by CT compared to the 15
patients whose post cycle 1 tumor response assessment
showed disease control by FDG-PET/CT were 113 (CI:
93, 167) versus 166 (CI: 86, 217) days, respectively. Median TTP of the seven patients whose post cycle 1 tumor
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response assessment showed progression by CT compared
to the 12 patients whose post cycle 1 tumor response
assessment showed PMD by FDG-PET/CT were 53 (CI:
49, 56) versus 61 (CI: 50, 105) days, respectively.

Discussion
This is the first prospective report to describe metabolic
tumor response assessment by FDG-PET/CT to singleagent cetuximab in patients with incurable SCCHN and to
compare these results to anatomic tumor response assessment by CT. Tumor response assessment by CT is a poor
method of determining benefit from cetuximab in patients
with incurable SCCHN, as judged by the disparity between
a high disease control rate (46%) and the short TTP
(70 days) [1]. We determined agreement in treatment decision using a clinically relevant definition: tumor response
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FDG-PET/CT

Diagnostic CT

Pretherapy

SUVmax = 12.6

After 1 Cycle of
Cetuximab

SUVmax = 23
Figure 2. Discordant CT and FDG-PET/CT in a patient (#26) with recurrent left hypopharyngeal squamous cell carcinoma. Transaxial FDG-PET/CT
(PET, left; fused PET/CT, middle; CT, right) and contrast-enhanced diagnostic CT images pretherapy (upper row) and after 1 cycle of cetuximab
(lower row). The SUVmax within the recurrent left hypopharyngeal mass increased from 12.6 pretherapy to 23 after 1 cycle of cetuximab,
indicating progression, but the size of the mass was stable on the diagnostic CT scan. SUVmax, maximum standardized uptake value; FDG-PET/CT,
F-18 fluorodeoxyglucose positron emission tomography/computed tomography.

assessment by CT and FDG-PET/CT resulted in the same
decision to either continue cetuximab (if disease control)
or to stop cetuximab (if progression). Disagreement in
treatment decision between CT and FDG-PET/CT would in
theory lead to different decisions about continuation of cetuximab following cycle 1. We investigated whether TTP
differed in patients with disease control (PR/SD) by CT
after cycle 1 based on the agreement/disagreement with
FDG-PET/CT. Note that cetuximab was continued after
cycle 1 in patients with disease control by CT, even if the
FDG-PET/CT showed PMD. Cetuximab was discontinued
after cycle 1 with progression by CT. In the 20 patients with
disease control by CT after cycle 1 of cetuximab, median
TTP was 166 days (CI: 86, 217) if the FDG-PET/CT
showed disease control and 105 days (CI: 66, 159) if the
FDG-PET/CT showed progression (P < 0.0001). These
data suggest that patients with disease control by CT following cycle 1 of cetuximab but with progression by FDGPET/CT (25% of this group) are benefitting less from the
cetuximab in comparison to those in whom there is agreement in the two imaging modalities, and thus, may be candidates for alternative therapy.
We stratified patients based on the agreement between
the two imaging modalities in either disease control or
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progression after cycle 1 of cetuximab and then compared
TTP between the two imaging modalities in each tumor
response group. Median TTP of the 20 patients whose
post cycle 1 tumor response assessment showed disease
control by CT compared to the 15 patients with disease
control by FDG-PET/CT were different (109 [CI: 93, 167]
vs. 166 [CI: 86, 217] days, respectively). Median TTP of
the patients whose post cycle 1 tumor response assessment showed progression by CT compared to the patients
with PMD by FDG-PET/CT were similar (53 [CI: 49, 56]
vs. 61 [CI: 50, 105] days, respectively). These data suggest
that FDG-PET/CT is a better predictor of TTP than CT
for patients with disease control after cycle 1 of
cetuximab.
The primary objective of this trial was to compare the
SUVmax of target lesions as assessed by FDG-PET/CT
before and after 8 weeks of cetuximab. The mean percent
change of SUVmax of target lesion(s) after cycle 1 was
21% (range: +72% to 81%) for the 27 evaluable
patients. The change in mean SUVmax of the target lesions
after cycle 1 was ≥20% decrease in 12 patients, ≥20%
increase in five patients, and between these parameters in
10 patients. For comparison, one study observed >25%
decrease in SUVmax of target lesion(s) in 18 of 19 patients

1499

FDG-PET/CT & CT, Response to Cetuximab

after 2 weeks of cetuximab given preoperatively to treatment-na€ıve SCCHN patients scheduled for primary curative surgery [5]. However, another smaller trial observed
a mean percent decrease in SUVmax of target lesion(s) of
only 11.1% (range 0 to 24.4) after 2 weeks of cetuximab given before radiation therapy and concurrent
cetuximab [12].
Interestingly, a ≥10% decrease in SUVmax of the target
lesion(s) in association with an increase in the number,
SUV and/or size of the nontarget lesions consistent with
overall PMD by FDG-PET/CT occurred in five patients
(19%) in our study. This observation may reflect the heterogeneity of metastatic tumor deposits within a patient
such that one lesion may be responsive to cetuximab,
whereas another lesion(s) may be resistant. Genetic diversity of metastatic tumor deposits within a patient may be
the mechanism of this observation [13].
Studies in other malignancies responsive to EGFR
inhibitors have examined the utility of FDG-PET/CT. In
advanced nonsmall cell lung cancer (NSCLC), FDG-PET/
CT was found to be a predictor of nonprogression (measured by CT), progression-free survival, and OS with
erlotinib therapy [14]. Patients with mutated EGFR compared to wild-type EGFR were found to have a greater
percent reduction in SUVpeak with erlotinib. These data
link proportional reduction in SUVpeak with benefit of
single-agent EGFR inhibition in NSCLC, analogous to
our observations with EGFR inhibition by cetuximab in
incurable SCCHN. Other preclinical [15] and clinical
studies [16–18] showed a correlation of tumor response
to EGFR inhibition in NSCLC to early reduction in SUV
as assessed by FDG-PET/CT, particularly in tumors with
EGFR mutations.
Limitations of our trial include the small number of
evaluable patients, absence of randomization to continue
cetuximab or change therapy based on the tumor
response to cycle 1 assessed by CT or FDG-PET/CT, and
single-institution experience. FDG-PET/CT was performed without IV iodine contrast; however, two recent
surveys found that there was wide variability in whether
IV contrast was administered with FDG-PET/CT [19, 20].
The majority of facilities perform noncontrast-enhanced
FDG-PET/CT. It is also possible that PET with radiotracers that measure other functional tumor characteristics
such as proliferation (18F-fluorothymidine) may be complementary to or better than FDG-PET/CT in assessing
tumor response to cetuximab [21]. Several patients developed progressive disease before completing cycle 1, suggesting that FDG-PET/CT may be best tested earlier in
treatment or that FDG-PET/CT may have had no role in
these patients. However, our study is an important step
forward to address an unmet need in the development of
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methods that allow for more accurate assessment of benefit of cetuximab in patients with SCCHN.
The limited number of evaluable patients in our trial
precludes firm conclusions; however, several observations
generate testable hypotheses. In this prospective trial, we
show that FDG-PET/CT may be better than CT in assessing
benefit of single-agent cetuximab in patients with incurable
SCCHN. Patients with disease control by CT following
cycle 1 of cetuximab but with progression by FDG-PET/CT
(25% of this group) are benefitting less so or not at all from
the cetuximab. In addition, FDG-PET/CT was a better predictor of TTP than CT in patients with disease control as
assessed by CT after cycle 1 of cetuximab. It is important
to develop methods that more accurately assess efficacy of
cetuximab in patients with incurable SCCHN since this
costly targeted agent benefits a minority of patients. These
observations provide evidence to perform a controlled trial
to validate the findings.
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